LncRNA AL645608.3 mediates malignant progression of acute myeloid leukemia.

Jin-Hua Yan, Kai-Qiong Liao, Ling Yao, Jian-Lan Chen, Li-Fang Xiong, Xu-Zhang Tao
Author Information
  1. Jin-Hua Yan: School of Information Management, Jiangxi University of Finance and Economics Nanchang 330013, Jiangxi, China.
  2. Kai-Qiong Liao: Department of Hematology, The First Hospital of Nanchang Nanchang 330008, Jiangxi, China.
  3. Ling Yao: Department of Gastroenterology, The First Hospital of Nanchang Nanchang 330008, Jiangxi, China.
  4. Jian-Lan Chen: Department of Hematology, The First Hospital of Nanchang Nanchang 330008, Jiangxi, China.
  5. Li-Fang Xiong: Department of Hematology, The First Hospital of Nanchang Nanchang 330008, Jiangxi, China.
  6. Xu-Zhang Tao: Department of Nuclear Medicine, The First Hospital of Nanchang Nanchang 330008, Jiangxi, China.

Abstract

OBJECTIVE: To investigate the role of lncRNA AL645608.3 in the malignant progression of acute myeloid leukemia (AML) cells and explore relevant molecular mechanisms.
METHODS: The expression level of AL645608.3 was measured in AML cell lines (THP-1, HL-60, KG-1, and AML-193) via real-time quantitative polymerase chain reaction (RT-qPCR). Small hairpin RNA (shRNA) and open reading frame of AL645608.3 were cloned into lentiviral vectors and were infected into THP-1 and AML-193 cells. The expression of casitas B-lineage lymphoma (CBL), interferon regulatory factor 6 (IRF6), and interferon beta 1 (IFNB1) was detected through RT-qPCR, and western blot. Co-immunoprecipitation (Co-IP) on IRF6 was conducted. Matrix metalloprotease-9 (MMP-9) activity was evaluated via gelatin zymography assay.
RESULTS: LncRNA AL645608.3 was expressed in the four AML cell lines (THP-1, HL-60, KG-1, and AML-193). Silencing AL645608.3 mitigated the expression of IRF6 and IFNB1 but elevated the expression of CBL in THP-1 cells. Oppositely, AL645608.3 overexpression up-regulated the expression of IRF6 and IFNB1 but decreased the expression of CBL in AML-193 cells. Co-IP results proved that AL645608.3 could directly mediate IRF6 activity in THP-1 and AML-193 cells. MMP-9 activity was decreased by AL645608.3 knockdown and was improved by AL645608.3 overexpression in AML-193 cells.
CONCLUSION: AL645608.3 is expressed in different AML cell lines, and mediates the expression of CBL, IRF6, IFNB1, and MMP-9. These findings might deepen our comprehension of the molecular mechanisms underlying AML.

Keywords

References

  1. J Cell Mol Med. 2019 Mar;23(3):1852-1864 [PMID: 30515972]
  2. J Exp Clin Cancer Res. 2021 Oct 6;40(1):312 [PMID: 34615546]
  3. Am J Hematol. 2023 Mar;98(3):502-526 [PMID: 36594187]
  4. Onco Targets Ther. 2020 Feb 19;13:1519-1531 [PMID: 32110049]
  5. J Autoimmun. 2017 Jun;80:85-94 [PMID: 28284523]
  6. Int J Biol Sci. 2017 Sep 5;13(9):1180-1191 [PMID: 29104509]
  7. J Clin Oncol. 2020 Sep 10;38(26):2993-3002 [PMID: 32673171]
  8. Cell Signal. 2019 Oct;62:109327 [PMID: 31152845]
  9. Pharmacol Rev. 2022 Jul;74(3):712-768 [PMID: 35738680]
  10. J Cell Biochem. 2018 Sep;119(9):7790-7799 [PMID: 29904939]
  11. Blood. 2021 Apr 22;137(16):2209-2220 [PMID: 33512474]
  12. Nucleic Acids Res. 2007;35(15):5232-41 [PMID: 17675303]
  13. Cancer Biol Ther. 2019;20(6):799-811 [PMID: 30739523]
  14. J Cancer. 2021 Apr 17;12(11):3393-3406 [PMID: 33976749]
  15. Nature. 2019 Oct;574(7777):249-253 [PMID: 31578523]
  16. Clin Cancer Res. 2009 Apr 1;15(7):2238-47 [PMID: 19276253]
  17. Cell Death Dis. 2020 Jun 11;11(6):447 [PMID: 32527996]
  18. Apoptosis. 2022 Aug;27(7-8):531-544 [PMID: 35618996]
  19. Blood Rev. 2019 Jul;36:70-87 [PMID: 31101526]
  20. Cell Mol Immunol. 2020 Jan;17(1):76-84 [PMID: 30275539]
  21. J Clin Oncol. 2018 Sep 10;36(26):2684-2692 [PMID: 30024784]
  22. Blood. 2023 Mar 30;141(13):1610-1625 [PMID: 36508699]
  23. Ann Surg Oncol. 2022 Oct;29(11):7180-7189 [PMID: 35726111]
  24. Adv Sci (Weinh). 2021 Nov;8(22):e2100914 [PMID: 34609794]
  25. N Engl J Med. 2022 Apr 21;386(16):1519-1531 [PMID: 35443108]
  26. Int J Mol Sci. 2021 Oct 22;22(21): [PMID: 34768865]
  27. Leuk Lymphoma. 2003 Nov;44(11):1935-41 [PMID: 14738146]
  28. Sensors (Basel). 2018 Sep 27;18(10): [PMID: 30262739]
  29. Clin Cancer Res. 1999 May;5(5):1115-24 [PMID: 10353746]
  30. Crit Rev Oncol Hematol. 2004 May;50(2):87-100 [PMID: 15157658]
  31. Nat Commun. 2021 Mar 29;12(1):1956 [PMID: 33782403]
  32. Leukemia. 2019 Feb;33(2):379-389 [PMID: 30555165]
  33. Nat Med. 2018 Jan;24(1):103-112 [PMID: 29227476]
  34. Exp Cell Res. 2023 Jan 15;422(2):113438 [PMID: 36435219]
  35. Exp Cell Res. 2020 Feb 1;387(1):111751 [PMID: 31805275]
  36. J Med Virol. 2023 Mar;95(3):e28637 [PMID: 36892175]
  37. J Med Virol. 2022 Feb;94(2):557-566 [PMID: 30968963]
  38. Blood. 2023 Jan 12;141(2):156-167 [PMID: 35714312]
  39. J Clin Oncol. 2023 Jun 1;41(16):2949-2962 [PMID: 36795987]
  40. J Biol Chem. 2010 Oct 15;285(42):32596-605 [PMID: 20622007]
  41. J Exp Clin Cancer Res. 2021 Nov 9;40(1):353 [PMID: 34753494]
  42. N Engl J Med. 2020 Aug 13;383(7):617-629 [PMID: 32786187]
  43. Am J Hematol. 2021 Feb 1;96(2):208-217 [PMID: 33119898]
  44. Autophagy. 2013 Mar;9(3):287-302 [PMID: 23221969]
  45. N Engl J Med. 2017 Aug 3;377(5):454-464 [PMID: 28644114]
  46. J Immunol Res. 2022 Oct 14;2022:2756611 [PMID: 36281357]

Word Cloud

Created with Highcharts 10.0.0AL6456083expressionIRF6cellsAML-193AMLTHP-1CBLIFNB1MMP-9acutemyeloidleukemiacelllinesactivitylncRNAmalignantprogressionmolecularmechanismsHL-60KG-1viaRT-qPCRinterferonCo-IPLncRNAexpressedoverexpressiondecreasedmediatesOBJECTIVE:investigateroleexplorerelevantMETHODS:levelmeasuredreal-timequantitativepolymerasechainreactionSmallhairpinRNAshRNAopenreadingframeclonedlentiviralvectorsinfectedcasitasB-lineagelymphomaregulatoryfactor6beta1detectedwesternblotCo-immunoprecipitationconductedMatrixmetalloprotease-9evaluatedgelatinzymographyassayRESULTS:fourSilencingmitigatedelevatedOppositelyup-regulatedresultsproveddirectlymediateknockdownimprovedCONCLUSION:differentfindingsmightdeepencomprehensionunderlying

Similar Articles

Cited By